June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Quality of Life Outcomes from a Randomized Controlled Trial Comparing Methotrexate to Mycophenolate Mofetil for Noninfectious Uveitis
Author Affiliations & Notes
  • Katherine M Niemeyer
    F. I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • John Alexander Gonzales
    F. I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Sivakumar R Rathinam
    Aravind Eye Care System, Madurai, India
  • Manohar Babu
    Aravind Eye Care System, Coimbatore, India
  • Radhika Thundikandy
    Aravind Eye Care System, Madurai, India
  • Anuradha Kanakath
    Aravind Eye Care System, Coimbatore, India
  • Travis C Porco
    F. I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California, United States
  • Erica Browne
    F. I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
  • Maya M Rao
    F. I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
  • Nisha Acharya
    F. I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Katherine Niemeyer, None; John Gonzales, None; Sivakumar Rathinam, None; Manohar Babu, None; Radhika Thundikandy, None; Anuradha Kanakath, None; Travis Porco, None; Erica Browne, None; Maya Rao, None; Nisha Acharya, AbbVie Inc. (F), Santen Pharmaceutical Co., Ltd. (F)
  • Footnotes
    Support  Funding for this trial was provided by That Man May See Foundation and The South Asia Research Fund at UCSF. Dr. Acharya is currently supported by an NEI U10 EY021125-01 grant. The UCSF Department of Ophthalmology is supported by the National Eye Institute and Research to Prevent Blindness Foundation grants.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2174. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Katherine M Niemeyer, John Alexander Gonzales, Sivakumar R Rathinam, Manohar Babu, Radhika Thundikandy, Anuradha Kanakath, Travis C Porco, Erica Browne, Maya M Rao, Nisha Acharya; Quality of Life Outcomes from a Randomized Controlled Trial Comparing Methotrexate to Mycophenolate Mofetil for Noninfectious Uveitis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2174.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the changes in quality of life in noninfectious uveitis patients treated with two of the most commonly prescribed antimetabolite treatments.

Methods : Secondary analysis of a multicenter, block-randomized, observer-masked clinical trial (ClinicalTrials.gov NCT01232920). Eighty patients at Aravind Eye Hospitals in Madurai and Coimbatore, India, with noninfectious intermediate, posterior, or panuveitis were randomized to receive oral methotrexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followed up monthly for 6 months. Best-corrected visual acuity, IND-VFQ, and SF-36 were obtained at enrollment and at 6 months (or prior in the event of early treatment failure). Changes in quality of life scores were compared using Wilcoxon signed-rank testing. The associations with visual acuity, treatment arm, and treatment outcome, as defined by corticosteroid-sparing control of inflammation, were assessed using linear regression models.

Results : IND-VFQ scores, on average, increased by 9.2 points from trial enrollment to 6 months (95% CI: 4.9, 13.5, P <0.001). While the SF-36 physical component summary score did not significantly differ over the course of the trial, the mental component summary score decreased by 2.3 points (95% CI: -4.4, -0.1, P=0.04) and the vitality subscale decreased by 3.5 points (95% CI: -5.6, -1.4, P=0.001). Patients that achieved corticosteroid sparing control of inflammation had an average 4.3 point higher increase in general health scores than patients who did not (95% CI: 0.3, 8.2, P=0.04). Quality of life scores did not differ between treatment arms. Linear regression modeling showed a 3.2 point improvement in IND-VFQ score for every 5 letter improvement in visual acuity (95% CI: 1.9, 4.3; P<0.001).

Conclusions : Although uveitis treatment was associated with a significant increase in vision and vision-related quality of life, patient-reported physical health did not change after 6 months of treatment and mental health decreased. Despite improved visual outcomes, uveitis patients receiving systemic immunosuppressive therapy may experience a deterioration in overall health-related quality of life.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×